QD202

QD202 is a small molecule neuroprotective agent developed by Shanghai Kweitec Biotechnology for the treatment of acute ischemic stroke (AIS). It acts as a first-in-class inhibitor of the protein-protein interaction between postsynaptic density protein 95 (PSD-95) and neuronal nitric oxide synthase (nNOS). During an ischemic stroke, excessive glutamate release leads to the overactivation of NMDA receptors, which, through the PSD-95/nNOS complex, triggers the overproduction of nitric oxide and subsequent excitotoxic neuronal death. By uncoupling the PSD-95/nNOS interaction, QD202 prevents this toxic signaling cascade without interfering with the normal catalytic activity of nNOS or the structural functions of PSD-95. This targeted approach aims to reduce brain infarct volume and improve neurological recovery in patients following a stroke.